All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2024-06-07T08:11:41.000Z

EHA 2024 abstracts: What’s hot in ALL?

By Abhilasha Verma, Quintina Dawson
Featured
Andrea Biondi
André Baruchel
Anita Rijneveld
Charles Mullighan
Elias Jabbour
Emmanuelle Clappier
Franco Locatelli
Hervé Dombret
Jan Cools
José María Ribera
Kjeld Schmiegelow
Mark Litzow
Nicola Gökbuget
Oliver Ottmann
Sabina Chiaretti
Wendy Stock
Jun 7, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

Bookmark this article

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Hybrid Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies for ALL

S111

Blinatumomab for first line treatment in intermediate and high risk Down Syndrome B-cell acute lymphoblastic leukaemia: Initial findings from the ALLTOGETHER1 DS TRIAL

S112

Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL – Final results of the ALLG ALL09 "SUBLIME" STUDY

S113

Blinatumomab added to prephase and consolidation therapy in adult B-ALL: A comparison of the consecutive HOVON-100 AND H-146 studies

S115

Ponatinib versus imatinib in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in the phase 3 PHALLCON trial: In depth responder analysis

P397

Augmented use of L-asparaginase markedly improves the treatment result of AYA ALL patients: Result of prospective MRD 2014 study conducted by Fukuoka Blood And Marrow Transplantation Group (FBMTG)

P398

Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the phase 2 PONALFIL trial

P400

Busulfan plus cyclophosphamide vs. Total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia 

P407

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931

P409

Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: Multicentre, single arm, phase 2 study

P411

A full pediatric regimen for adult patients with Philadelphia negative acute lymphoblastic leukemia achieves excellent outcomes with acceptable toxicity

P416

Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): Safety run-in follow-up for the phase 3 GOLDEN GATE study.

P427

Combination of third generation TKI olverembatinib and chemotherapy or blinatumomab for new diagnosed adult Ph+ ALL patients

P1740

Improving outcome in elderly Philadelphia negative acute lymphoblastic leukemia: Feasibility and efficacy of an intensive PEG-asparaginase-based regimen


Treatments for relapsed/refractory ALL

S110

WU-CART-007, an allogeneic CAR-T cell targeting CD7, is highly effective against relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)

S114

Obecabtagene autoleucel in adult relapsed/refractory B-cell acute lymphoblastic leukemia: Survival and potential impact of CAR T-cell persistence and stem cell transplantation in the FELIX Study

P395

Subsequent allotransplant in adults with advanced acute lymphoblastic leukemia after CD19 CAR T-cell therapy: A multi-center randomized controlled trial

P402

Efficacy and tolerance of modified HyperCVAD, blinatumomab, and TKI, combination as a treatment for relapsed or refractory Ph+ B-cell acute lymphoblastic leukemia

P429

Five-year outcome of CD19 combined with CD22 CAR T-cell therapy in B-ALL patients relapsed after allo-transplantation


Biomarkers, prognosis, and biology 

S116

Early response refines end of induction measurable residual disease stratification in T-cell acute lymphoblastic leukaemia 

P403

MRD monitoring in childhood Ph-positive acute lymphoblastic leukemia: Prognostic significance and correlation between multiparameter flow cytometry and RT-QPCR

P419

Impact of NGS MRD and clonal evolution on clinical prognosis in pediatric Ph+ ALL patients 

P368

The genomic landscape of relapsed infant and childhood KNT2A-rearranged acute leukemia 


Real-world outcomes

P413

Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia with marrow blasts <5%, including patients (pts) with NGS MRD negative disease

P424

Real-world utilization of blinatumomab in adult and pediatric patients with acute lymphoblastic leukemia in France: Results from the ATHENA study

EHA24 Top Abstracts

To download this document, click below.

Download here

More about...
EHA 2024

Your opinion matters

HCPs, what is your preferred format for educational content on the ALL Hub?
2 votes - 80 days left ...

Related articles

Add bookmark

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?

During the recent ALL Hub Steering Committee meeting, members discussed strategies to optimize CAR T-cell therapy outcomes in pediatric, adolescents, and...

Dec 21, 2023
Add bookmark

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?

During the recent ALL Hub Steering Committee meeting, members discussed strategies to optimize CAR T-cell...

Dec 21, 2023
Add bookmark

How I sequence treatment for R/R B-ALL

During the last steering committee meeting (SC), held on May 19, 2022, the SC members discussed sequencing treatment in R/R B-ALL. The session was chaired by Hervé Dombret and included Wendy Stock, André...

Jul 28, 2022
Add bookmark

How I sequence treatment for R/R B-ALL

During the last steering committee meeting (SC), held on May 19, 2022, the SC members discussed sequencing treatment in R/R B-ALL. The session was chaired by...

Jul 28, 2022

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox